ALIGOS THERAPEUTICS INC (ALGS) Stock Price, Forecast & Analysis
NASDAQ:ALGS • US01626L2043
ALGS Key Statistics, Chart & Performance
The current stock price of ALGS is 6.91 USD. In the past month the price decreased by -16.34%. In the past year, price decreased by -70.81%.
ALGS Technical Analysis
ALGS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALGS. The financial health of ALGS is average, but there are quite some concerns on its profitability.
ALGS Financial Highlights
Over the last trailing twelve months ALGS reported a non-GAAP Earnings per Share(EPS) of -10.08. The EPS increased by 24.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -78.77% | ||
| ROE | -120.37% | ||
| Debt/Equity | 0 |
ALGS Forecast & Estimates
11 analysts have analysed ALGS and the average price target is 69.56 USD. This implies a price increase of 906.71% is expected in the next year compared to the current price of 6.91.
For the next year, analysts expect an EPS growth of 23.93% and a revenue growth -31.96% for ALGS
ALGS Ownership
ALGS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALGS
Company Profile
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2020-10-16. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Company Info
ALIGOS THERAPEUTICS INC
One Corporate Dr., 2Nd Floor, 2nd Floor
South San Francisco CALIFORNIA 94080 US
CEO: Lawrence M. Blatt
Employees: 70
Phone: 18004666059
ALIGOS THERAPEUTICS INC / ALGS FAQ
Can you describe the business of ALIGOS THERAPEUTICS INC?
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2020-10-16. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
What is the stock price of ALIGOS THERAPEUTICS INC today?
The current stock price of ALGS is 6.91 USD. The price decreased by -1.14% in the last trading session.
Does ALIGOS THERAPEUTICS INC pay dividends?
ALGS does not pay a dividend.
What is the ChartMill rating of ALIGOS THERAPEUTICS INC stock?
ALGS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is ALGS stock listed?
ALGS stock is listed on the Nasdaq exchange.
What do analysts say about ALIGOS THERAPEUTICS INC (ALGS) stock?
11 analysts have analysed ALGS and the average price target is 69.56 USD. This implies a price increase of 906.71% is expected in the next year compared to the current price of 6.91.
Is ALIGOS THERAPEUTICS INC (ALGS) expected to grow?
The Revenue of ALIGOS THERAPEUTICS INC (ALGS) is expected to decline by -31.96% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.